Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Ani Marrs

Senior Marketing Manager - Entellect

About the author: I’m currently responsible for Entellect – Elsevier’s data integration platform, designed to help pharma, chemicals and other Life Science organisations by enriching and harmonizing proprietary and external data so that their researchers can focus on answering the bigger questions that will improve patient outcomes. I’m particularly interested in the increase in predictive analytics within drug discovery, FAIR data and how new insights can be gleaned when information is connected across silos.

Posts by Ani Marrs

Bringing Scalability Into Chemistry Modeling

Posted on November 18th, 2020 in Chemistry

Synthetic chemistry has been with us for centuries, but it is now entering a new frontier. Big data, AI and machine learning are unlocking a predictive power that is transforming the conceptualization and optimization of synthetic routes.


BCG – COVID-19 Hackathon Challenge Now Extended Through End of Year

Posted on October 23rd, 2020 in COVID-19

A renewed interest in whether the BCG vaccine (for tuberculosis) could also have an application for COVID-19 has been on the rise, as evidenced by this recent Cell publication, the University of Exeter’s involvement in the BRACE Trial and ongoing general press coverage. Furthermore, the list of clinical trials focusing on this area is continuing to grow (and is available here).


Insights begin with clean, reusable data

Posted on August 24th, 2020 in Pharma R&D

Good data practices lead to better research outcomes. To learn more about why clean, reusable data is critical to R&D, take a look at this helpful new infographic that demonstrates how Entellect is centered around the importance of reusable data, irrespective of scientific domain.


To Be a Digital Pharma Player, You Need Data – Reusable Data

Posted on July 21st, 2020 in Pharma R&D

A new paper published in Drug Discovery Today finds that the pharmaceutical industry is in an “early mature” phase of using artificial intelligence in R&D, which means that major industry players are interested in and pursuing AI, but not as actively as one might expect. For instance, they note that of the top 20 pharma companies that they looked at, only two (Novartis and Johnson & Johnson) have commercialized AI through products and services so far.


  1. 1
  2. 2